Pieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97M 2022/03/01 12:18:37 Seeking Alpha
Pieris Pharmaceuticals press release (PIRS): FY GAAP EPS of -$0.71 beats by $0.17.Revenue of $31.41M (+7.1% Y/Y) beats by $5.97M.
Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group? 2022/02/28 20:05:47 Benzinga
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for Pieris Pharmaceuticals Inc (NASDAQ: PIRS ), Baidu Inc (NASDAQ: BIDU ) and Cronos Group Inc (NASDAQ: CRON ): Traders and investors will be watching for Pieris’s fourth-quarter earnings report, confirmed for Tuesday’s pre-market session. According to analyst consensus estimates, Pieris is expected to report an EPS loss of 3 cents on revenue of $2.45 million. Pieris reported in November an EPS loss of … Full story available on Benzinga.com
Pieris Pharmaceuticals Q4 2021 Earnings Preview 2022/02/28 19:44:50 Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.25 and the consensus…
Pieris Pharmaceuticals begins dosing in phase 2 gastric cancer study 2022/01/14 13:26:21 Seeking Alpha
Pieris Pharmaceuticals (PIRS) said the first patient was dosed in a phase 2 study of cinrebafusp alfa (PRS-343) to treat HER2-expressing gastric cancer.The trial is evaluating
Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Dont? 2021/12/15 19:41:56 FXNews24
Investors in Pieris Pharmaceuticals, Inc. PIRS need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 18, 2021 $17.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market  The post Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Dont? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Expected to Post Quarterly Sales of $7.98 Million 2021/11/02 06:02:42 Transcript Daily
Equities analysts predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will report $7.98 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Pieris Pharmaceuticals earnings. The highest sales estimate is $11.80 million and the lowest is $4.15 million. Pieris Pharmaceuticals posted sales of $2.94 million during the same quarter 
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Update 2021/10/31 12:55:00 Dakota Financial News
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 1,610,000 shares, a growth of 49.1% from the September 30th total of 1,080,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is 
Pieris Pharmaceuticals (PIRS) to Release Earnings on Tuesday 2021/10/27 12:42:41 Dakota Financial News
Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce its earnings results before the market opens on Tuesday, November 2nd. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, 
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021 2021/10/26 12:08:00 FinanzNachrichten
BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® t…
Stock Mover: Ashford Hospitality Trust, Inc. (NYSE:AHT), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) 2021/07/12 23:06:23 Stock Equity
Ashford Hospitality Trust, Inc. (AHT) with the stream of 1.51% also noticed, India Pieris Pharmaceuticals, Inc. (PIRS) encountered a rapid change of -1.04% in the last hour of Mondays trading The post Stock Mover: Ashford Hospitality Trust, Inc. (NYSE:AHT), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) appeared first on Stocks Equity .
ITM Appoints Dr. Sabine Daugelat as Chief Operating Officer 2021/07/06 09:00:00 Business Wire
GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM AG, a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sabine Daugelat to its management team as Chief Operating Officer (COO) of the clinical development of ITM. Dr. Daugelat has over 18 years of experience in the pharmaceutical and biotechnology industry and was most recently Executive Director, Head of Project Leadership at Pieris Pharmaceuticals. In her role at ITM, she will be responsible for the operationa
This Risky Micro-Cap Could Pay Off Big 2021/06/30 12:31:00 The Motley Fool
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
Pieris Pharmaceuticals Shares Rise 19% After Getting Orphan Drug Status 2021/06/30 02:28:51 MarketWatch
Pieris Pharmaceuticals Shares Rise 19% After Getting Orphan Drug Status MarketWatch